Physician profile
Allison C Whitton
NPI 1194767244
$1,383.45
in general payments reported to CMS, 2019-2025
24 companies · $173 in 2025
The $173 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $73.13 · 2020: $67.92 · 2021: $15.01 · 2022: $350 · 2023: $334 · 2024: $370 · 2025: $173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $778 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $777.81 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $230.90 | 2019-2024 | Veozah, Myrbetriq |
| Intuitive Surgical, INC. | $190.66 | 2022-2023 | |
| Abbvie INC. | $119.10 | 2019-2023 | Lo Loestrin Fe |
| Radius Health, INC. | $109.24 | 2025 | Tymlos |
| Aspira Women'S Health INC | $105.41 | 2022 | |
| Hologic Sales and Service, LLC | $102.24 | 2024 | Fluent Fluid Management System, Novasure, Myosure Tissue Removal Device |
| Mayne Pharma Commercial LLC | $82.46 | 2024-2025 | |
| Exeltis, USA INC. | $49.35 | 2019-2025 | Slynd |
| Applied Medical Resources Corporation | $45.30 | 2022 | |
| Biogen, INC. | $44.56 | 2024-2025 | Zurzuvae |
| Masimo Corporation | $42.21 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $41.51 | 2019-2024 | |
| Organon LLC | $39.24 | 2024 | |
| Avion Pharmaceuticals | $28.08 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $22.73 | 2024 | Gardasil 9, Gardasil |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $21.73 | 2023 | Myfembree |
| Sage Therapeutics, LLC | $18.77 | 2022 | |
| Seqirus USA INC | $18.76 | 2024 | Fluad, Flucelvax |
| Therapeuticsmd, INC. | $17.45 | 2022 | |
| Coopersurgical, INC. | $14.31 | 2024 | Paragard T 380a |
| Pfizer INC. | $14.06 | 2023 | |
| Ethicon US, LLC | $13.85 | 2022 | |
| Mylan Pharmaceuticals INC. | $11.53 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Whitton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.